Abstract
Purpose
Breast cancer treatment-related lymphedema (BCRL) is a common co-morbidity of breast cancer therapies, yet factors that contribute to BCRL progression remain incompletely characterized. We investigated whether magnetic resonance imaging (MRI) measures of subcutaneous adipose tissue were uniquely elevated in women with BCRL.
Methods
MRI at 3.0 T of upper extremity and torso anatomy, fat and muscle tissue composition, and T2 relaxometry were applied in left and right axillae of healthy control (n = 24) and symptomatic BCRL (n = 22) participants to test the primary hypothesis that fat-to-muscle volume fraction is elevated in symptomatic BCRL relative to healthy participants, and the secondary hypothesis that fat-to-muscle volume fraction is correlated with MR relaxometry of affected tissues and BCRL stage (significance criterion: two-sided p < 0.05).
Results
Fat-to-muscle volume fraction in healthy participants was symmetric in the right and left sides (p = 0.51); in BCRL participants matched for age, sex, and BMI, fat-to-muscle volume fraction was elevated on the affected side (fraction = 0.732 ± 0.184) versus right and left side in controls (fraction = 0.545 ± 0.221, p < 0.001). Fat-to-muscle volume fraction directly correlated with muscle T2 (p = 0.046) and increased with increasing level of BCRL stage (p = 0.041).
Conclusion
Adiposity quantified by MRI is elevated in the affected upper extremity of women with BCRL and may provide a surrogate marker of condition onset or severity.
Clinical trial
NCT02611557.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Data availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
Code availability
Code generated during the current study is available from the corresponding author on reasonable request.
References
U.S. Breast Cancer Statistics (2021) Retrieved from https://www.breastcancer.org/symptoms/understand_bc/statistics
DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515
Boyages J, Xu Y, Kalfa S, Koelmeyer L, Parkinson B, Mackie H, Viveros H, Gollan P, Taksa L (2017) Financial cost of lymphedema borne by women with breast cancer. Psychooncology 26(6):849–855
Rockson SG, Rivera KK (2008) Estimating the population burden of lymphedema. Ann N Y Acad Sci 1131:147–154
Rockson SG, Keeley V, Kilbreath S, Szuba A, Towers A (2019) Cancer-associated secondary lymphoedema. Nat Rev Dis Primers 5(1):22
Chen CM, Cano SJ, Klassen AF, King T, McCarthy C, Cordeiro PG, Morrow M, Pusic AL (2010) Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J 16(6):587–597
Penha TR, Botter B, Heuts EM, Voogd AC, von Meyenfeldt MF, van der Hulst RR (2016) Quality of life in patients with breast cancer-related lymphedema and reconstructive breast surgery. J Reconstr Microsurg 32(6):484–490
Shah C, Arthur DW, Wazer D, Khan A, Ridner S, Vicini F (2016) The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. Cancer Med 5(6):1154–1162
McDuff SGR, Mina AI, Brunelle CL, Salama L, Warren LEG, Abouegylah M, Swaroop M, Skolny MN, Asdourian M, Gillespie T et al (2019) Timing of lymphedema after treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys 103(1):62–70
Michelotti A, Invernizzi M, Lopez G, Lorenzini D, Nesa F, De Sire A, Fusco N (2019) Tackling the diversity of breast cancer related lymphedema: perspectives on diagnosis, risk assessment, and clinical management. Breast 44:15–23
Sayegh HE, Asdourian MS, Swaroop MN, Brunelle CL, Skolny MN, Salama L, Taghian AG (2017) Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions. Curr Breast Cancer Rep 9(2):111–121
Rockson SG (2010) Current concepts and future directions in the diagnosis and management of lymphatic vascular disease. Vasc Med 15(3):223–231
Crescenzi R, Donahue PMC, Hartley KG, Desai AA, Scott AO, Braxton V, Mahany H, Lants SK, Donahue MJ (2017) Lymphedema evaluation using noninvasive 3T MR lymphangiography. J Magn Reson Imaging 46(5):1349–1360
Borri M, Schmidt MA, Gordon KD, Wallace TA, Hughes JC, Scurr ED, Koh DM, Leach MO, Mortimer PS (2015) Quantitative contrast-enhanced magnetic resonance lymphangiography of the upper limbs in breast cancer related lymphedema: an exploratory study. Lymphat Res Biol 13(2):100–106
Lu Q, Xu J, Liu N (2010) Chronic lower extremity lymphedema: a comparative study of high-resolution interstitial MR lymphangiography and heavily T2-weighted MRI. Eur J Radiol 73(2):365–373
Cellina M, Martinenghi C, Panzeri M, Soresina M, Menozzi A, Daniele G, Oliva G (2021) Noncontrast MR lymphography in secondary lower limb lymphedema. J Magn Reson Imaging 53(2):458–466
Donahue PMC, Crescenzi R, Lee C, Garza M, Patel NJ, Petersen KJ, Donahue MJ (2020) Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema. Breast Cancer Res Treat 183(1):83–94
Donahue PM, Crescenzi R, Scott AO, Braxton V, Desai A, Smith SA, Jordi J, Meszoely IM, Grau AM, Kauffmann RM et al (2017) Bilateral changes in deep tissue environment after manual lymphatic drainage in patients with breast cancer treatment-related lymphedema. Lymphat Res Biol 15(1):45–56
Crescenzi R, Donahue PMC, Mahany H, Lants SK, Donahue MJ (2020) CEST MRI quantification procedures for breast cancer treatment-related lymphedema therapy evaluation. Magn Reson Med 83(5):1760–1773
Donahue MJ, Donahue PC, Rane S, Thompson CR, Strother MK, Scott AO, Smith SA (2016) Assessment of lymphatic impairment and interstitial protein accumulation in patients with breast cancer treatment-related lymphedema using CEST MRI. Magn Reson Med 75(1):345–355
Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1–2):3–20
Huang LH, Elvington A, Randolph GJ (2015) The role of the lymphatic system in cholesterol transport. Front Pharmacol 6:182
Wong BW, Wang X, Zecchin A, Thienpont B, Cornelissen I, Kalucka J, Garcia-Caballero M, Missiaen R, Huang H, Bruning U et al (2017) The role of fatty acid beta-oxidation in lymphangiogenesis. Nature 542(7639):49–54
Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA (2006) Secondary lymphedema in the mouse tail: lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 72(3):161–171
Rutkowski JM, Markhus CE, Gyenge CC, Alitalo K, Wiig H, Swartz MA (2010) Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. Am J Pathol 176(3):1122–1129
Tashiro K, Feng J, Wu SH, Mashiko T, Kanayama K, Narushima M, Uda H, Miyamoto S, Koshima I, Yoshimura K (2017) Pathological changes of adipose tissue in secondary lymphoedema. Br J Dermatol 177(1):158–167
Li CY, Kataru RP, Mehrara BJ (2020) Histopathologic features of lymphedema: a molecular review. Int J Mol Sci 21(7):2546
Rane S, Donahue PM, Towse T, Ridner S, Chappell M, Jordi J, Gore J, Donahue MJ (2013) Clinical feasibility of noninvasive visualization of lymphatic flow with principles of spin labeling MR imaging: implications for lymphedema assessment. Radiology 269(3):893–902
Brorson H, Ohlin K, Olsson G, Karlsson MK (2009) Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol 7(1):3–10
Idy-Peretti I, Bittoun J, Alliot FA, Richard SB, Querleux BG, Cluzan RV (1998) Lymphedematous skin and subcutis: in vivo high resolution magnetic resonance imaging evaluation. J Invest Dermatol 110(5):782–787
Borri M, Gordon KD, Hughes JC, Scurr ED, Koh DM, Leach MO, Mortimer PS, Schmidt MA (2017) Magnetic resonance imaging-based assessment of breast cancer-related lymphoedema tissue composition. Invest Radiol 52(9):554–561
Sen Y, Qian Y, Koelmeyer L, Borotkanics R, Ricketts R, Mackie H, Lam TC, Ho Shon K, Suami H, Boyages J (2017) Breast cancer-related lymphedema: differentiating fat from fluid using magnetic resonance imaging segmentation. Lymphat Res Biol. https://doi.org/10.1089/lrb.2016.0047
Crescenzi R, Donahue PM, Braxton VG, Scott AO, Mahany HB, Lants SK, Donahue MJ (2018) 3.0 T relaxation time measurements of human lymph nodes in adults with and without lymphatic insufficiency: implications for magnetic resonance lymphatic imaging. NMR Biomed 31(12):e4009
Gold GE, Han E, Stainsby J, Wright G, Brittain J, Beaulieu C (2004) Musculoskeletal MRI at 3.0 T: relaxation times and image contrast. Am J Roentgenol 183(2):343–351
Kataru RP, Park HJ, Baik JE, Li C, Shin J, Mehrara BJ (2020) Regulation of lymphatic function in obesity. Front Physiol 11:459
Wang Y, Oliver G (2010) Current views on the function of the lymphatic vasculature in health and disease. Genes Dev 24(19):2115–2126
Fu MR, Axelrod D, Guth AA, Fletcher J, Qiu JM, Scagliola J, Kleinman R, Ryan CE, Chan N, Haber J (2015) Patterns of obesity and lymph fluid level during the first year of breast cancer treatment: a prospective study. J Pers Med 5(3):326–340
Ching DL, Anderson A, Kumarasinghe SP (2015) Lower limb lymphoedema and obesity: a much-neglected association. Br J Hosp Med (Lond) 76(9):542–543
Yamamoto T, Yamamoto N, Yamashita M, Furuya M, Hayashi A, Koshima I (2016) Efferent lymphatic vessel anastomosis: supermicrosurgical efferent lymphatic vessel-to-venous anastomosis for the prophylactic treatment of subclinical lymphedema. Ann Plast Surg 76(4):424–427
Yamamoto T, Yoshimatsu H, Yamamoto N (2016) Complete lymph flow reconstruction: a free vascularized lymph node true perforator flap transfer with efferent lymphaticolymphatic anastomosis. J Plast Reconstr Aesthet Surg 69(9):1227–1233
Hadamitzky C, Zaitseva TS, Bazalova-Carter M, Paukshto MV, Hou L, Strassberg Z, Ferguson J, Matsuura Y, Dash R, Yang PC et al (2016) Aligned nanofibrillar collagen scaffolds—guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials 102:259–267
Tian W, Rockson SG, Jiang X, Kim J, Begaye A, Shuffle EM, Tu AB, Cribb M, Nepiyushchikh Z, Feroze AH et al (2017) Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal3920
Chang DW, Dayan J, Greene AK, MacDonald JK, Masia J, Mehrara B, Neligan PC, Nguyen D (2021) Surgical treatment of lymphedema: a systematic review and meta-analysis of controlled trials. Results of a consensus conference. Plast Reconstr Surg 147(4):975–993
Acknowledgements
We are grateful to Christopher Thompson, Clair Jones, Marisa Bush, Joshua Hageman, Charles Nockowski, and Ryan Robinson for experimental support.
Funding
This research was funded by Grant Nos. NIH/NINR 1R01NR015079, NIH/NHLBI 1R01HL155523, the Lipedema Foundation (LF) Postdoctoral Research Fellowship, LF Collaborative Grant #12, American Heart Association (AHA) 18CDA34110297, and AHA 19IPLOI34760518. Imaging experiments were performed in the Vanderbilt Human Imaging Core using research resources supported by the NIH grant 1S10OD021771-01. Recruitment through www.ResearchMatch.org and services at the Clinical Research Center are supported by the National Center for Advancing Translational Sciences (NCATS) Clinical Translational Science Award (CTSA) Program, award number 5UL1TR002243-03. REDCap resources were provided by NCATS/NIH UL1 TR000445. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation and data collection were performed by RC, PD, MD, MG, CL, and NP. Analyses were performed by RC, MD, PD, SJ, and VG. The first draft of the manuscript was written by RC and MD. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
PMCD is a paid consultant for PureTech Health and Tactile Medical and has received clinical and imaging grants from LymphaTouch Inc. MJD receives research-related support from Philips North America; is a paid consultant for Pfizer Inc, Global Blood Therapeutics, and LymphaTouch; is a paid advisory board member for Novartis and bluebird bio; receives research funding from Pfizer Inc; and is the CEO of Biosight, LLC which provides healthcare technology consulting services. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Ethical approval
This study was approved by the Vanderbilt University Medical Center Institutional Review Board.
Consent to participate
All participants provided written informed consent before study participation.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Crescenzi, R., Donahue, P.M.C., Garza, M. et al. Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema. Breast Cancer Res Treat 191, 115–124 (2022). https://doi.org/10.1007/s10549-021-06419-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-021-06419-w